INCYTE WKN: 896133 ISIN: US45337C1027 Kürzel: INCY Forum: Aktien Thema: Hauptdiskussion

Hab nach den Zahlen die erste Position gekauft und gerade die zweite Position

-8% 🙈 trotz guten zahlen?

Der Kurs zeigt in die verkehrte Richtung 😭

Incyte Corp. übertrifft im vierten Quartal mit einem Gewinn je Aktie von $0,93 die Analystenschätzungen von $0,75. Umsatz mit $789,51 Mio. über den Erwartungen von $662,94 Mio. Quelle: Guidants News: 09.02.21, 13:20

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-Acceptance-and-Priority-Review-of-BLA-for-Retifanlimab-as-a-Potential-Treatment-for-Patients-with-Squamous-Cell-Carcinoma-of-the-Anal-Canal-SCAC/default.aspx

Geht da heute was ?

https://www.businesswire.com/news/home/20201207005129/en/Incyte-Announces-Parsaclisib-Treatment-Results-in-High-Rate-of-Rapid-and-Durable-Responses-in-Patients-with-Relapsed-or-Refractory-B-Cell-Non-Hodgkin-Lymphomas

Incyte EPS misses by $0.53, misses on revenue https://seekingalpha.com/news/3631986-incyte-eps-misses-0_53-misses-on-revenue Incyte (NASDAQ:INCY): Q3 Non-GAAP EPS of $0.23 misses by $0.53; GAAP EPS of -$0.07 misses by $0.57. Revenue of $620.64M (+12.5% Y/Y) misses by $1.84M.

Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients https://seekingalpha.com/news/3623006-lilly-incytes-baricitinib-shows-additional-benefit-in-hospitalized-covidminus-19-patients

Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics https://m.marketscreener.com/news/latest/Nimble-Announces-Strategic-Research-Collaboration-with-Incyte-to-Discover-Novel-Peptide-Based-Therap--31484994/

https://www.businesswire.com/news/home/20200918005082/en/Incyte-Announces-Encouraging-Results-From-Phase-2-Trial-of-Retifanlimab-INCMGA0012-in-Patients-With-Previously-Treated-Advanced-Squamous-Cell-Carcinoma-of-the-Anal-Canal Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time https://www.marketwatch.com/story/shares-of-lilly-and-incyte-gain-after-late-stage-study-finds-their-arthritis-drug-can-help-reduce-covid-19-recovery-time-2020-09-14

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM https://www.businesswire.com/news/home/20200902005825/en/Incyte-Announces-Pivotal-GEOMETRY-mono-1-Study-Results

Wird eher Morphosys betreffen, denke ich.

Müsste doch steigen oder??

MorphoSys' tafasitamab added to U.S. treatment guidelines for type of blood cancer https://seekingalpha.com/news/3606850-morphosys-tafasitamab-added-to-u-s-treatment-guidelines-for-type-of-blood-cancer MorphoSys AG (NASDAQ:MOR) and collaborator/licensee Incyte (NASDAQ:INCY) announce that Monjuvi (tafasitamab-cxix) has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-cell lymphomas.